Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.41 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.39 |
| ▸ | NMT1 | P30419 | 2/20 | 0.39 |
| ▸ | AURKA | O14965 | 6/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14375262 | 0.84 | KDM4E (0.51) | MAPTRECQLTLR9TLR8TLR7 | |
| SCHEMBL21101179 | 0.81 | PRKAA2 (0.41) | MAPTRECQLTLR9TLR8TLR7 | |
| SCHEMBL20328913 | 0.80 | EGFR (0.52) | MAPTRECQLAURKAKDM4EKCNH2 | |
| SCHEMBL12384858 | 0.80 | MAPT (0.41) | MAPTRECQLTLR9TLR8TLR7 | |
| SCHEMBL18932538 | 0.80 | MAPT (0.41) | MAPTRECQLTLR9TLR8TLR7 | |
| SCHEMBL18932537 | 0.78 | KDM4E (0.48) | MAPTRECQLAURKAKDM4EKCNH2 | |
| SCHEMBL15214318 | 0.78 | L3MBTL1 (0.46) | MAPTRECQLTLR9TLR8TLR7 | |
| SCHEMBL15468520 | 0.78 | TLR9 (0.41) | MAPTRECQLTLR9TLR8TLR7 | |
| SCHEMBL12424320 | 0.77 | TLR9 (0.38) | MAPTRECQLTLR9TLR8TLR7 | |
| SCHEMBL2004023 | 0.77 | MAPT (0.46) | MAPTRECQLTLR9TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110098272-A1 | Novel Compounds As Casein Kinase Inhibitors | PFIZER INC | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | MAPT 4361/4885RECQL 112/4885TLR9 2536/4885 |
| US-20110098272-A1 | Novel Compounds As Casein Kinase Inhibitors | CSNK1A1, CSNK1A1L, CSNK1G1 | MAPT 808/4885RECQL 2843/4885TLR9 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.